B3GALT9: A Drug Target / Disease Biomarker (G100288842)

Target Name: B3GALT9

NCBI ID: G100288842

B3GALT9

Other Name(s): putative UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase LOC402377 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 10 (putative) | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 pseudogene | LOC100288842 | beta-1,3-galactosyltransferase 9 | putative UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase LOC100288842 | B3GNT10

B3GALT9: A Drug Target / Disease Biomarker

B3GALT9 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the B3GALT family, which includes several similar proteins that are involved in the regulation of cellular processes such as cell adhesion, migration, and survival.

One of the unique features of B3GALT9 is its ability to interact with several different signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT. This makes it an attractive target for researchers who are interested in understanding the role of these signaling pathways in various biological processes.

In addition to its potential as a drug target, B3GALT9 has also been identified as a potential biomarker for several diseases. For example, it has been shown to be highly expressed in the brains of individuals with Alzheimer's disease, and may be involved in the development and progression of this debilitating neurological disorder.

Another potential application of B3GALT9 is its role in cancer progression. Several studies have shown that B3GALT9 is highly expressed in various types of cancer, and may be involved in the development and progression of these diseases. Therefore, researchers are exploring the potential of using B3GALT9 as a target for cancer therapies.

In addition to its potential as a drug or biomarker, B3GALT9 is also of interest to researchers who are interested in the regulation of cellular processes in general. The B3GALT family has been shown to play a role in the regulation of a wide range of cellular processes, including cell adhesion, migration, and survival. Therefore, researchers are interested in further studies of the B3GALT9 gene and its role in these processes.

Overall, B3GALT9 is a protein that has significant potential as a drug target or biomarker. Its ability to interact with multiple signaling pathways and its expression in a wide range of tissues make it an attractive target for researchers who are interested in understanding the role of this protein in various biological processes. Further studies are needed to fully understand the role of B3GALT9 in these processes and its potential as a drug or biomarker.

Protein Name: Beta-1,3-galactosyltransferase 9

Functions: Putative glycosyltransferase that could catalyze the transfer of galactose residues from UDP-alpha-D-galactose

The "B3GALT9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about B3GALT9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets